Bao Yu, Du Li-zhong, Shi Li-ping, Cheng Xiao-ying
Neonatal Intensive Care Unit, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhonghua Er Ke Za Zhi. 2010 Jul;48(7):510-3.
With the widespread application of peripherally inserted central catheters (PICC) in neonatal intensive care unit (NICU), the incidence of invasive fungal infections increased significantly than ever. The present study aimed to explore the clinical significance of oral fluconazole in premature infants with gestational age ≤ 32 weeks and/or birth weight ≤ 1500 grams who had catheter insertions.
This study enrolled 118 infants admitted between January 2006 and December 2007 who did not receive fluconazole prophylaxis (control group) and 106 infants admitted between January 2008 and June 2009 who received oral fluconazole prophylaxis (prophylaxis group). Statistical analyses were performed by using SPSS 11.5 software. The clinical characteristics and the risk factors for invasive fungal infection between the two groups were compared. Liver functions (alanine transaminase, ALT and direct bilirubin) were monitored to evaluate the safety of fluconazole prophylaxis.
Except for the proportion of infants born via vaginal delivery in the control group (56/118, 47.5%) was significantly lower than that in prophylaxis group (69/106, 65.1%, P = 0.007), there were no significant significant differences in the demographics and other baseline clinical characteristics between the two groups. There were no significant differences in the risk factors for invasive fungal infection between the two groups either. Nine infants developed invasive fungal infection in control group (7.6%), while no invasive fungal infection was found in prophylaxis group (0%, P = 0.01). Compared to infants in control group, those in prophylaxis group showed no significant changes in alanine transaminase ALT and direct bilirubin levels at 2 weeks and 4 weeks after fluconazole prophylaxis: the incidences of abnormal ALT and direct bilirubin levels were 8.5% (10/118) and 6.8% (8/118) in control group compared to 11.3% (12/106) and 8.5% (9/106) in prophylaxis group after 2 weeks (P = 0.47 and 0.63); the incidences of abnormal ALT and direct bilirubin levels were 3.4% (4/118) and 3.4% (4/118) in control group compared to 5.7% (6/106) and 8.5% (9/106) in prophylaxis group after 4 weeks (P = 0.62 and 0.15).
For infants with PICC insertions and gestational ages at birth ≤ 32 weeks and/or low birth weight ≤ 1500 grams, oral fluconazole is effective to prevent invasive fungal infection. Oral fluconazole in premature infants neither affected the liver function, nor increased the incidence of cholestasis.
随着外周静脉穿刺中心静脉导管(PICC)在新生儿重症监护病房(NICU)的广泛应用,侵袭性真菌感染的发生率比以往显著增加。本研究旨在探讨口服氟康唑对胎龄≤32周和/或出生体重≤1500克且已进行导管插入的早产儿的临床意义。
本研究纳入了2006年1月至2007年12月期间入院且未接受氟康唑预防治疗的118例婴儿(对照组)以及2008年1月至2009年6月期间入院且接受口服氟康唑预防治疗的106例婴儿(预防组)。使用SPSS 11.5软件进行统计分析。比较两组侵袭性真菌感染的临床特征和危险因素。监测肝功能(丙氨酸转氨酶、ALT和直接胆红素)以评估氟康唑预防治疗的安全性。
除对照组经阴道分娩的婴儿比例(56/118,47.5%)显著低于预防组(69/106,65.1%,P = 0.007)外,两组在人口统计学和其他基线临床特征方面无显著差异。两组侵袭性真菌感染的危险因素也无显著差异。对照组有9例婴儿发生侵袭性真菌感染(7.6%),而预防组未发现侵袭性真菌感染(0%,P = 0.01)。与对照组婴儿相比,预防组婴儿在氟康唑预防治疗后2周和4周时丙氨酸转氨酶ALT和直接胆红素水平无显著变化:对照组在2周后ALT和直接胆红素水平异常的发生率分别为8.5%(10/118)和6.8%(8/118),预防组分别为11.3%(12/106)和8.5%(9/106)(P = 0.47和0.63);对照组在4周后ALT和直接胆红素水平异常的发生率分别为3.4%(4/118)和3.4%(4/118),预防组分别为5.7%(6/106)和8.5%(9/106)(P = 0.62和0.15)。
对于进行PICC插入且出生胎龄≤32周和/或出生体重≤1500克的婴儿,口服氟康唑可有效预防侵袭性真菌感染。早产儿口服氟康唑既不影响肝功能,也不增加胆汁淤积的发生率。